Compare SBGI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | LBRX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.0M | 850.5M |
| IPO Year | 2023 | N/A |
| Metric | SBGI | LBRX |
|---|---|---|
| Price | $14.15 | $29.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $22.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 367.9K | 146.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $3,169,000,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.89 | $13.40 |
| 52 Week High | $17.88 | $33.47 |
| Indicator | SBGI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 53.07 |
| Support Level | $13.32 | $26.44 |
| Resistance Level | $15.49 | $33.47 |
| Average True Range (ATR) | 0.42 | 1.52 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 83.64 | 74.81 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.